contraception
Women's health · 2013–2025
7decisions
5medicines
4carried consumer input
18individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| etonogestrel with ethinylestradiol Contraception for women seeking a non-oral contraceptive preparation who have difficulty swallowing tablets, gastrointestinal disturbances (e.g.… | May 2025 | Recommended | input received |
| estetrol with drospirenone Oral contraceptive for women of reproductive age to prevent pregnancy. | Mar 2025 | Recommended | 1 individuals National Aboriginal Community Controlled Organisation |
| drospirenone Contraception in women. Drospirenone is a progestogen-only pill (POP) indicated for women requesting contraception, particularly those with contraindications… | Nov 2024 | Recommended | 17 individuals |
| medroxyprogesterone acetate Contraception in women, particularly in remote communities where it is a preferred form among Aboriginal and Torres Strait Islander women. | Nov 2023 | Recommended | none received |
| levonorgestrel Contraception for up to 5 years in women requesting contraception. | Mar 2019 | Recommended with restriction | input received |
| levonorgestrel Contraception for women requiring long-acting reversible contraception delivered via an intrauterine device. | Mar 2014 | Recommended with restriction | no section in document |
| levonorgestrel Contraception for up to three years using an intrauterine levonorgestrel system releasing approximately 12 micrograms per 24 hours. | Jul 2013 | Recommended | no section in document |
Who spoke
National Aboriginal Community Controlled Organisation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.